Studies on the inhibitory effect of isavuconazole on flumatinib metabolism in vitro and in vivo
As the validated agent for the treatment of chronic myelogenous leukemia (CML), flumatinib is a novel oral tyrosine kinase inhibitor (TKI) with higher potency and selectivity for BCR-ABL1 kinase compared to imatinib. Many patients experience aspergillosis infection and they may start using isavucona...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
Frontiers Media S.A.
2023-05-01
|
| Цуврал: | Frontiers in Pharmacology |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1168852/full |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|